Tau Screening Study in Patients With Early Symptomatic AD

Alzheimer Disease Clinical Trial

Official title:

A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03322462
• Other study ID #: 18F-AV-1451-A23
• Status: Completed
• Phase: Phase 2
• Start date: November 21, 2017
• Est. completion date: August 31, 2018

Study information

• Verified date: August 2020
• Source: Avid Radiopharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 155
• Est. completion date: August 31, 2018
• Est. primary completion date: August 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 85 Years

Eligibility

Inclusion Criteria:

• Men or women between the ages of 60 and 85 years of age at the time of consent

• Patients with gradual and progressive change in memory function for a period equal to or greater than six months

• Patients who have a Mini Mental State Examination (MMSE) score in the 20-27 range

• Patients who are willing to undergo a PET scan using flortaucipir F 18

• Patients who give informed consent or have a legally authorized representative (LAR) to consent for enrollment

Exclusion Criteria:

• Patients who lack adequate premorbid literacy, vision, or hearing to complete the required psychometric testing in the investigator's opinion

• Females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception methods. Females of childbearing potential must not be pregnant (negative serum ß-Human Chorionic Gonadotropin [HCG] at screening and negative urine ß-HCG prior to flortaucipir F 18 injection) or breastfeeding at screening. Females should agree to avoid becoming pregnant by refraining from sexual activity or using reliable contraceptive methods for 24 hours following flortaucipir F 18 injection administration.

• Have significant neurological disease affecting the Central Nervous System (CNS) (other than AD) that may affect cognition or ability to complete the study, including but not limited to, other types of dementia, serious brain infections, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).

• Patients with any current primary psychiatric diagnosis other than AD if, in the opinion of the investigator, the disorder/symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the patient's ability to complete the study (patients with history of schizophrenia or other chronic psychosis are excluded).

• Intend to use drugs known to significantly prolong the QT interval within 14 days or 5 half-lives (whichever is longer) of a scheduled screening/baseline flortaucipir F 18 PET scan, or have medical history of risk factors for Torsades du Pointes.

• Have an average electrocardiography (ECG) corrected QT (QTcF) interval measurement > 450 msec (men) or > 470 msec (women) at screening (as determined at the investigational site).

• Have ocular pathology that significantly limits ability to reliably evaluate vision or the retina.

• Have a history of alcohol or drug disorder (except tobacco use disorder) within 2 years before the screening visit

• Have a current serious or unstable illness including retinal, cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than 24 months.

• Has a history of cancer within the last five years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, non-progressive prostate cancer, or other cancers with low risk of recurrence or spread

• Patients with a past history (suspected or confirmed) of Hepatitis B or Hepatitis C

• History of vitiligo and/or current evidence of post-inflammatory hypopigmentation

• Have had prior treatment with a passive anti-amyloid immunotherapy less than five half-lives prior to randomization.

• Have previously participated in any other study investigating active immunization against amyloid beta (Aß)

• Patients that are currently enrolled in any other interventional clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study

• Contraindication to PET

• Has hypersensitivity to flortaucipir F 18 or any of its excipients

• Present or planned exposure to ionizing radiation that, in combination with the planned administration of study PET ligands, would result in a cumulative exposure that exceeds local recommended exposure limits

• Has previous magnetic resonance imaging (MRI) evidence of significant abnormality that would suggest another potential etiology for progressive dementia or a clinically significant finding that may impact patient's potential to safely participate in study

• Have contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker

• Have poor venous access

• Are investigator site personnel directly affiliated with this study and/or immediate families; immediate family is defined as a spouse, parent, child, or sibling (biological or legally adopted)

• Are Lilly employees or are employees of third-party organizations (TPOs) involved in a study that requires exclusion of their employees

• Are otherwise unsuitable for a study of this type in the opinion of the investigator

• Have received treatment with a stable dose of an acetylcholinesterase inhibitor (AChEI) and/or memantine for less than two months before randomization (if a patient has recently stopped an AChEI and/or memantine, he/she must have discontinued treatment at least two months before randomization).

• Current use of strong inducers of CYP3A

• Are currently on medication(s) known to significantly prolong the QT interval

• Have allergies to either monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone

• Have known allergies to LY3002813, related compounds, or any components of the formulation; or history of significant atopy

• Have known allergies to LY3202626, related compounds, or any components of the formulation

• Changes in concomitant medications that could potentially affect cognition and their dosing should be stable for at least one month before screening, and between screening and randomization (does not apply to medications discontinued due to exclusions or with limited duration of use, such as antibiotics)

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• Flortaucipir F18
370 megabecquerel (MBq) IV single-dose

Procedure:
• Brain PET Scan
positron emission tomography (PET) scan of the brain

Locations

Country	Name	City	State
Canada	Toronto Memory Program	Toronto	Ontario
United States	The Memory Clinic	Bennington	Vermont
United States	Brain Matters Research	Delray Beach	Florida
United States	Boston Center for Memory	Newton	Massachusetts
United States	Bioclinica (Compass Research)	Orlando	Florida
United States	Pacific Research Network	San Diego	California
United States	Syrentis Clinical Research	Santa Ana	California
United States	Axiom Clinical Research	Tampa	Florida
United States	Abington Neurological Associates	Willow Grove	Pennsylvania
United States	PMG Research	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Avid Radiopharmaceuticals

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Flortaucipir Qualitative Results (Visual Reads)	Flortaucipir PET scans were rated visually by an expert reader as follows: Not consistent with an AD pattern (tAD-), Moderate AD pattern (tAD+), or Advanced AD pattern and likely to progress (tAD++). Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.	baseline scan
Primary	Flortaucipir Quantitative Results (SUVr)	Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain. Visual read categories as described for previous measure. Eligibility for AACG study was determined from the flortaucipir PET scan quantitation (SUVr; see below) according to protocol-specified criteria that excluded subjects with tau PET signal that was above or below study criteria.	baseline scan